Skip to main content
Premium Trial:

Request an Annual Quote

Bayer-Genzyme Deal Yields Access to Small-Molecule Library

Premium

LEVERKUSEN, Germany--Bayer here has announced a collaboration with Genzyme to accelerate identification of drug development targets. Candidates will come from Genzyme's small-molecule compound library and be analyzed with Bayer's high-speed robotic screening equipment. The deal could be worth as much as $35 million to Genzyme in fees and milestone payments, the company said.

Terms of the collaboration include an up-front payment to Genzyme for access to the company's library, with milestone payments coming as selected compounds proceed through clinical trials. "The unique chemistry technology developed by Genzyme is an ideal combination with Bayer's expertise in high-technology robotic screening methods," commented Wolfgang Hartwig, Bayer's head of worldwide pharmaceutical research.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.